Amyotrophic Lateral Sclerosis
Conditions
Keywords
ALS, VEGF165, Safety, Intracerebroventricular, Infusion, Implantable
Brief summary
This is an open label safety and tolerability continuation study of intracerebroventricular administration of sNN0029, containing the growth factor VEGF165, in patients with amyotrophic lateral sclerosis that have previously participated in study sNN0029-001. The intention of the study is to investigate safety and tolerability of intracerebroventricular administration of sNN0029 and whether it can improve motor function and prolong survival in patients with ALS.
Interventions
DRUGsNN0029
ICV infusion
Sponsors
Medtronic
ICON Clinical Research
Newron Sweden AB
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Clinical diagnosis of ALS classified as definite, or probable with or without additional laboratory evidence, according to the revised WFN El Escorial criteria (Appendix B). 2. Previous participation in study sNN0029-001 with completion of 12 weeks study drug administration. 3. To have completed the investigations associated with safety in study sNN0029-001 without development of clinically significant safety concerns. 4. Patient has been given written and verbal information about the continuation study, has had the opportunity to ask questions about the study, and understands the time and procedural commitments. 5. Patient has given oral and / or signed consent (written) to participate in the study. In the event that a patient who gives oral informed consent is not physically able to sign the informed consent form (ICF) due to disease progression, a witness may sign the ICF on the patient's behalf.
Exclusion criteria
1. Hypertension defined as blood pressure \>160 mmHg systolic or \>90 mmHg diastolic. 2. Proliferative retinopathy. 3. Non-proliferative retinopathy of moderate severity or higher. 4. Concurrent clinically significant dementia as determined by the investigator. 5. Concurrent clinically significant depression as determined by the investigator. 6. Need for administration of any antiplatelet or anticoagulant medication (e.g. aspirin, Plavix, non-steroidal anti-inflammatory drugs \[NSAIDs\]). Low dose aspirin or occasional use of NSAIDs is allowed (See Appendix E). 7. Clinically significant abnormalities in haematology or clinical chemistry parameters as assessed by the investigator. 8. For female patients, ongoing pregnancy or planned pregnancy 9. Breast feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and tolerability through assessments of adverse events, vital signs, clinical laboratory tests, MRI of brain, fundus photography and device performance as characterized by catheter tip placement and infusion accuracy | multiple assessments over 120 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Disease activity as measured by ALS functional rating scale (FRS) - VEGF concentrations in CSF - Possible VEGF antibodies in plasma | Multiple assessments over 120 weeks |
Countries
Belgium
Outcome results
None listed